Next Article in Journal
Metal Complexes of Diisopropylthiourea: Synthesis, Characterization and Antibacterial Studies
Next Article in Special Issue
Roles of Oxidative Stress, Apoptosis, PGC-1α and Mitochondrial Biogenesis in Cerebral Ischemia
Previous Article in Journal / Special Issue
Manganese Superoxide Dismutase: Guardian of the Powerhouse
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2011, 12(10), 7163-7185; doi:10.3390/ijms12107163

Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy

National Research Laboratory for Mitochondrial Signaling, Department of Physiology, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, Busan, 614-735, Korea
Author to whom correspondence should be addressed.
Received: 29 July 2011 / Revised: 30 September 2011 / Accepted: 20 October 2011 / Published: 21 October 2011
(This article belongs to the Special Issue Oxidative Stress and Mitochondria)
View Full-Text   |   Download PDF [544 KB, uploaded 19 June 2014]   |  


Mitochondria are involved either directly or indirectly in oncogenesis and the alteration of metabolism in cancer cells. Cancer cells contain large numbers of abnormal mitochondria and produce large amounts of reactive oxygen species (ROS). Oxidative stress is caused by an imbalance between the production of ROS and the antioxidant capacity of the cell. Several cancer therapies, such as chemotherapeutic drugs and radiation, disrupt mitochondrial homeostasis and release cytochrome c, leading to apoptosome formation, which activates the intrinsic pathway. This is modulated by the extent of mitochondrial oxidative stress. The peroxiredoxin (Prx) system is a cellular defense system against oxidative stress, and mitochondria in cancer cells are known to contain high levels of Prx III. Here, we review accumulating evidence suggesting that mitochondrial oxidative stress is involved in cancer, and discuss the role of the mitochondrial Prx III antioxidant system as a potential target for cancer therapy. We hope that this review will provide the basis for new strategic approaches in the development of effective cancer treatments.
Keywords: ROS; mitochondria; peroxiredoxin III; cancer; antioxidant; oxidative stress; therapy ROS; mitochondria; peroxiredoxin III; cancer; antioxidant; oxidative stress; therapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Song, I.-S.; Kim, H.-K.; Jeong, S.-H.; Lee, S.-R.; Kim, N.; Rhee, B.D.; Ko, K.S.; Han, J. Mitochondrial Peroxiredoxin III is a Potential Target for Cancer Therapy. Int. J. Mol. Sci. 2011, 12, 7163-7185.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top